Search results for "stroke."

showing 10 items of 1178 documents

Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction

2017

Abstract Objectives The study sought to assess the outcome of percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) in patients with low left ventricular ejection fraction (LVEF) (≤35%). Background Data regarding the outcome of PCI in patients with low LVEF affected by CTO are scarcely reported. Methods The authors performed a prospective longitudinal multicenter study including consecutive patients undergoing elective PCI of CTOs. Patients were subdivided into 3 groups: group 1 (LVEF ≥50%), group 2 (LVEF 35% to 50%), and group 3 (LVEF ≤35%). Results A total of 839 patients (mean 64.6 ± 10.5 years of age, 87.7% men) underwent CTO PCI attempts. Baseline LVEF ≤35% was pr…

Malemedicine.medical_specialtyanimal structuresTime Factorsmedicine.medical_treatment610 Medicine & healthKaplan-Meier Estimate030204 cardiovascular system & hematologyCoronary AngiographyDisease-Free SurvivalVentricular Function Left2705 Cardiology and Cardiovascular Medicinechronic total occlusion; ischemic LV dysfunction; left ventricular ejection fraction; PCI; Cardiology and Cardiovascular Medicinechronic total occlusionischemic LV dysfunctionleft ventricular ejection fractionPCI03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRisk FactorsInternal medicinemedicineHumansIn patientcardiovascular diseases030212 general & internal medicineLongitudinal StudiesProspective Studieschronic total occlusionAgedProportional Hazards ModelsEjection fractionbusiness.industryPercutaneous coronary interventionleft ventricular ejection fractionPCIStroke VolumeRecovery of FunctionMiddle AgedSurgeryEuropeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseCardiology10209 Clinic for CardiologyFemalebusinessCardiology and Cardiovascular Medicineischemic LV dysfunction
researchProduct

Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

2020

Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the r…

Malemedicine.medical_specialtyaspirinHealth Toxicology and Mutagenesisdipyridamolelcsh:MedicineStroke.Review030204 cardiovascular system & hematology03 medical and health sciencesTherapeutic approach0302 clinical medicinePharmacotherapyDouble-Blind MethodpreventionSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineStrokeAgedclopidogrelAspirinPreventive strategybusiness.industrylcsh:RPublic Health Environmental and Occupational HealthMiddle AgedClopidogrelmedicine.diseasestrokecombined drug therapyClinical trialDiabetes Mellitus Type 2Ischemic Attack TransientStroke preventionDrug Therapy CombinationFemalebusinesscilostazolPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drugInternational Journal of Environmental Research and Public Health
researchProduct

Vitamin D: a target for improving post-stroke prognosis?

2015

Malemedicine.medical_specialtybusiness.industryDepressionMEDLINEmedicine.diseaseStrokeNeurologyInternal medicineVitamin D and neurologyPost strokeMedicineHumansFemaleNeurology (clinical)Vitamin DbusinessStrokeDepression (differential diagnoses)European journal of neurology
researchProduct

Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure

2020

Abstract Background Carbohydrate antigen 125 (CA125) and B-type natriuretic peptides are surrogate markers of congestion in patients with acute heart failure (AHF). The aim of the study was to assess the association between CA125 and NT-proBNP and congestion parameters in patients with AHF. Methods and results Prospective multicentre observational study that included 191 patients hospitalised for AHF. We recorded the presence of pleural effusion, peripheral oedema and inferior vena cava (IVC) diameter during the first 24–48 h after admission and evaluated their independent association with CA125 concentrations and the amino-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP). Th…

Malemedicine.medical_specialtyendocrine system diseasesmedicine.drug_classPleural effusionPeripheral edemaInferior vena cavaVentricular Function LeftInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansIn patientProspective StudiesAgedAged 80 and overHeart FailureEjection fractionbusiness.industryStroke VolumeMiddle AgedPrognosismedicine.diseasePeptide Fragmentsmedicine.veinHeart failureCardiologySerum ca125Femalemedicine.symptombusinessBiomarkersMedicina Clínica (English Edition)
researchProduct

Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre …

2021

Summary Background Systematic electrocardiogram (ECG) monitoring improves detection of covert atrial fibrillation in stroke survivors but the effect on secondary prevention is unknown. We aimed to assess the effect of systematic ECG monitoring of patients in hospital on the rate of oral anticoagulant use after 12 months. Methods In this investigator-initiated, randomised, open-label, parallel-group multicentre study with masked endpoint adjudication, we recruited patients aged at least 18 years with acute ischaemic stroke or transient ischaemic attack without known atrial fibrillation in 38 certified stroke units in Germany. Patients were randomly assigned (1:1) to usual diagnostic procedur…

Malemedicine.medical_specialtyepidemiology [Atrial Fibrillation]methods [Electrocardiography]Populationdiagnosis [Ischemic Stroke]030204 cardiovascular system & hematologyBrain Ischemia03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsInternal medicineIschaemic strokeAtrial Fibrillationdiagnosis [Brain Ischemia]medicineepidemiology [Brain Ischemia]HumansIn patientMyocardial infarctionddc:610educationepidemiology [Ischemic Stroke]Ischemic StrokeMonitoring PhysiologicAgedAged 80 and overeducation.field_of_studybusiness.industryphysiopathology [Ischemic Stroke]Hazard ratiodiagnosis [Atrial Fibrillation]Atrial fibrillationOdds ratioMiddle Agedmethods [Monitoring Physiologic]medicine.diseasephysiopathology [Atrial Fibrillation]physiopathology [Brain Ischemia]3. Good healthFemaleNeurology (clinical)Open labelbusiness030217 neurology & neurosurgery
researchProduct

Leisure-time cross-country skiing is associated with lower incidence of hypertension:A prospective cohort study

2019

Abstract Objective: The prospective relationship between cross-country skiing and hypertension is uncertain. We aimed to assess the associations of leisure time cross-country skiing habits with incident hypertension in a general population. Methods: The frequency, average duration, and intensity of leisure cross-country skiing were assessed at baseline using a 12-month physical activity questionnaire in the Kuopio Ischemic Heart Disease prospective study of 1809 middle-aged men without hypertension. Hazard ratios [95% confidence intervals (CIs)] were calculated. Results: New onset diagnosis of hypertension was observed in 279 participants during a median (interquartile range) follow-up of 2…

Malemedicine.medical_specialtyhypertensionPhysiologyPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineLeisure ActivitiesInterquartile rangeSkiingInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineProspective StudieseducationProspective cohort studyStrokeeducation.field_of_studybusiness.industryPhysical activityIncidence (epidemiology)IncidenceHazard ratioMiddle Agedmedicine.diseasestrokeConfidence intervalHypertensionhigh-intensity exercise trainingCardiology and Cardiovascular MedicinebusinessRisk Reduction Behaviorhuman activitiescross-country skiingCohort study
researchProduct

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study

2020

Altres ajuts: Conselleria d'Educació, Investigació, Cultura i Esport GV/2018/116 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40…

Malemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemLeft ventricular ejection fractionCardiac magnetic resonancemedicine.medical_treatmentMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme InhibitorsPilot Projects030204 cardiovascular system & hematologyVentricular Function LeftPCSK9Angiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineCardiac magnetic resonance imagingOriginal Research ArticlesInternal medicinemedicineST‐segment elevation myocardial infarctionHumansST segmentOriginal Research Article030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedKillip classEjection fractionmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionStroke VolumeMiddle Agedmedicine.diseaseST-segment elevation myocardial infarctionlcsh:RC666-701Heart failureCardiologyST Elevation Myocardial InfarctionProprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study

2021

Abstract Background Women with atrial fibrillation (AF) may be treated less actively with oral anticoagulation (OAC) than men. Patients and methods We assessed sex differences in the implementation of stroke risk stratification with CHADS2 and CHA2DS2-VASc scores and reasons not to use OAC in 1747 AF patients suffering their first cerebrovascular event after the AF diagnosis. Results Women were older and had more often a high stroke risk (CHADS2/CHA2DS2-VASc ≥2) than men (p < .001). On admission, 46.4% of women and 48.2% of men were on OAC with no sex difference (p = .437). However, of patients without OAC, 74.4% of women and 49.5% of men should have been on OAC based on CHADS2/CHA2DS2-VASc…

Malemedicine.medical_specialtylääkemääräyksetsukupuolierotAtrial fibrillation (AF)oral anticoagulation (OAC)030204 cardiovascular system & hematologyRisk AssessmentArticleStroke riskCHADS203 medical and health sciencesSex Factors0302 clinical medicineInternal medicineAtrial Fibrillationparasitic diseasesmedicinesexHumanscardiovascular diseases030212 general & internal medicineOral anticoagulationEvent (probability theory)business.industryWarfarinAnticoagulantsAtrial fibrillationGeneral Medicineeteisvärinämedicine.diseasehyytymisenestohoitoStrokeCerebrovascular DisordersCHA2DS2-VAScatrial fibrillation (AF)sydän- ja verisuonitauditCardiologyFemaleWarfarinbusinessResearch Articlemedicine.drugAnnals of Medicine
researchProduct

Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhan…

2013

Background: Contrast echocardiography improves accuracy and reduces interreader variability on left ventricular (LV)functional analyses inthe settingof two-dimensional (2D) echocardiography. Theneedfor contrast imaging using three-dimensional (3D) echocardiography is less defined. The aim of this multicenter study was to define the accuracy and interreader agreement of unenhanced and contrast-enhanced 2D and 3D echocardiography for the assessment of LV volumes and ejection fraction (EF). Methods: A multicenter, open-label study was conducted including 63 patients, using intrasubject comparisons to assess the agreement of unenhanced and contrast-enhanced 2D and 3D echocardiography as well as…

Malemedicine.medical_specialtymedia_common.quotation_subjectEchocardiography Three-DimensionalSulfur HexafluorideContrast MediaMagnetic Resonance Imaging CineSensitivity and SpecificityVentricular Dysfunction LeftCardiac magnetic resonance imagingInternal medicinemedicineContrast (vision)HumansRadiology Nuclear Medicine and imagingSingle-Blind MethodRadionuclide VentriculographyPhospholipidsmedia_commonObserver VariationEjection fractionmedicine.diagnostic_testbusiness.industryReproducibility of ResultsThree dimensional echocardiographyStroke VolumeOrgan SizeConfidence intervalEuropeContrast echocardiographyCardiologyFemaleCardiology and Cardiovascular MedicinebusinessCardiac magnetic resonanceNuclear medicine3d echocardiographyJournal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
researchProduct

Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.

2018

Abstract Background Recent ESC guidelines on heart failure (HF) have introduced a new phenotype based on left ventricular ejection fraction (LVEF), called the mid-range (HFmrEF). This phenotype falls between the classical reduced (HFrEF) and preserved (HFpEF) HF phenotypes. We aimed to characterize the HFmrEF biomarker profile and outcomes. Methods 1069 consecutive ambulatory patients were included in the study (age 66.2 ± 12.8 years); 800 with HFrEF (74.8%), 134 with HFmrEF (12.5%), and 135 with HFpEF (12.5%). We measured serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), soluble suppression of tumorigenicity (ST2), galectin-…

Malemedicine.medical_specialtymedicine.drug_classGalectin 3030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineTroponin TInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumans030212 general & internal medicineSoluble transferrin receptorAgedAged 80 and overHeart FailureEjection fractionbiologyTroponin Tbusiness.industryHazard ratioStroke VolumeStroke volumeMiddle Agedmedicine.diseasePrognosisPeptide FragmentsDeathHeart failureChronic Diseasebiology.proteinCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational journal of cardiology
researchProduct